Drug Development Drug Pricing Drug Manufacturing Manufacturing Drug Safety Market Trends Generic Drugs Clinical Trials Market Competition Vaccine Development Research and Development Regulatory Affairs Regulations Drug Distribution Market Dynamics Obesity Treatments Biotechnology Drug Manufacturers Drug Accessibility Drug Approval Obesity Drugs Drug Costs Drug Marketing Generic Medications Pharmaceutical Companies Drug Production Drug Research Drug Affordability Pharmacy Chains Cancer Treatment Drug Provision Drug Discovery Market Impact Drug Importation Generic Medicines Corporate Strategy Regulatory Approval Biopharmaceuticals Drug Exports Regulatory Issues Generics Mergers and Acquisitions Drug Competition Medicine Production Active Pharmaceutical Ingredients Acquisitions Pharmacy Benefit Managers (PBMs) Drug Supply Chain Generic Drugmakers FDA Approval Process Abortion Pill Dispensation Birth Control Drug Shortages Alzheimer's Disease Treatment Weight-Loss Drugs Government Regulation Vaccine Production Pricing Strategies Healthcare Innovations Drug Price Negotiations Eli Lilly and Co FDA Authority Drug Production Costs Research and Development Costs Greed Drug Patents Group Purchasing Organizations Regulation Drug Supply Drug Negotiation Oncology Health Communication Drug Availability Specialty Medicines Drug Approval Processes Drug Innovation Addiction Treatment Partnerships Market Expansion Innovation Artificial Intelligence Healthcare Companies Indian Pharmaceutical Alliance Drug Imports Market Leaders Sales Strategies Drug Sales FDA Investment Projects Pharmaceutical Executives Drug Trials Quality Control Profitability Drug Procurement Affordability Investment Obesity Treatment Analytical Testing Drug Prices Generics Market
The filings set an April 13, 2026 deadline for investors to seek lead-plaintiff status over alleged misstatements tied to AMT-130.
